COVID-19-Related Treatment Cancellations and Oncology Patients' Psychological Health in Nigeria.

Objective: To explore the association between COVID-19-related cancer treatment cancellations and the psychological health of cancer patients in Nigeria.Methods: We analyzed data collected from 15 outpatient cancer clinics, comprising 1,097 patients between April to July 2020. Study outcome was ten psychological impacts, including feeling down, stressed, and unable to access treatment due to COVID-19 (used as continuous and categorical variable (0-3,4-7,8+ events). The independent variable was treatment cancellations due to COVID-19 categorized as 0, 1, and 2+ cancellations. Confounders included religion, ethnicity, income, cancer diagnosis/type, and treatment received. Stata/SE.v.17 was used to perform all analyses. P values of ≤0.05 were deemed statistically significant.Results: Of the 1,097 cancer patients, 65.7% were female, with a mean age (SD) of 49.4 (13.8) years. Most patients (50.3%) reported four to seven psychological health events. Cancer patients who reported two/more treatment cancellations made up only 12.8% of the study sample but accounted for a greater proportion of psychological impacts (23.5%; P<0.001). In the adjusted model, cancer patients with one treatment cancellation (Coef: 0.195, 95%CI: 0.089-0.302) and those with two/more cancellations (Coef: 0.379, 95%CI: 0.255-0.504) had a significantly higher risk of psychological health impacts than those with no treatment cancellations.Conclusion: More than half of our sample of primarily adult female cancer patients reported major psychological health effects due to COVID-19. Cancer patients who experienced at least one treatment cancellation had a higher risk of psychological health consequences than those who did not. The implications of our findings and how to mitigate the impact of COVID-19 on oncology service disruptions are discussed.

Challenges and opportunities for implementing hypofractionated radiotherapy in Africa: lessons from the HypoAfrica clinical trial.

The rising cancer incidence and mortality in sub-Saharan Africa (SSA) warrants an increased focus on adopting or developing approaches that can significantly increase access to treatment in the region. One such approach recommended by the recent Lancet Oncology Commission for sub-Saharan Africa is hypofractionated radiotherapy (HFRT), which can substantially increase access to radiotherapy by reducing the overall duration of time (in days) each person spends being treated. Here we highlight challenges in adopting such an approach identified during the implementation of the HypoAfrica clinical trial. The HypoAfrica clinical trial is a longitudinal, multicentre study exploring the feasibility of applying HFRT for prostate cancer in SSA. This study has presented an opportunity for a pragmatic assessment of potential barriers and facilitators to adopting HFRT. Our results highlight three key challenges: quality assurance, study harmonisation and machine maintenance. We describe solutions employed to resolve these challenges and opportunities for longer term solutions that can facilitate scaling-up use of HFRT in SSA in clinical care and multicentre clinical trials. This report provides a valuable reference for the utilisation of radiotherapy approaches that increase access to treatment and the conduct of high-quality large-scale/multi-centre clinical trials involving radiotherapy. Trial registration: Not available yet.

Chest X-rays of newborns in a medical facility: variation between the entrance skin dose measurements using the indirect and direct methods for clinical dose audit.

PURPOSE: This study aims to determine the mean and 75th percentile entrance skin dose (ESDcal) from anteroposterior (AP) chest X-rays using machine parameters (indirect method). Also, a comparison was made between the ESDcal and already determined thermoluminescent dosimeter (TLD) measurements (ESDTLD) from a previous study from the same patients' data. In addition, the results were compared to similar articles, where the direct and indirect methods were used in estimating ESD to newborns. MATERIALS AND METHODS: The study determined the digital radiography (DR) X-ray machine output using a calibrated XR Multidetector (silicon photodiode). X-ray machine milliampere-seconds (mAs), peak kilovoltage (kVp), focus to detector distance (FDD) and focus to skin distance (FSD) were used from a previous study. The mean kVp and mAs were 56.63 (52-60) and 5.7 (5-6.3) and the patient thickness was 9.5 (8-11.5) cm. RESULTS: The mean ESDs of the newborn between 0 and 28 days were 0.67 ± 0.09 mGy, and the 75th percentile was 0.75 mGy. The effective dose (E) for the 40 patients was 0.19 mSv and the estimated prenatal cancer risk ranged from (5-24.7) 10-6 Sv-1. The variation between the indirect and the direct methods for assessing ESD was 39.6 (33.7-45.1)%. CONCLUSION: The 75th percentile ESD was the highest compared to the American College of Radiology-American Association of Physicists in Medicine-Society for Pediatric Radiology (ACR-AAPM-SPR), European Commission (EC) and United Kingdom (UK) reports. Comparison of both methods for assessing ESD was within 40% as compared to other studies. Based on the above results, the indirect method can be implemented for clinical dose audit.